As of 2026-03-25, the Intrinsic Value of GT Biopharma Inc (GTBP) is -4.10 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.47 USD, the upside of GT Biopharma Inc is -976.11%.
Based on its market price of 0.47 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 976.11%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.10 - -4.10 | -4.10 | -976.11% |
| P/E | (17.90) - (21.02) | (19.09) | -4173.9% |
| DDM - Stable | (5.08) - (22.93) | (14.01) | -3089.4% |
| DDM - Multi | (2.05) - (7.93) | (3.34) | -813.5% |
| Market Cap (mil) | 15.08 |
| Beta | -0.05 |
| Outstanding shares (mil) | 32.18 |
| Enterprise Value (mil) | 8.27 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.27% |
| Cost of Debt | 5.00% |
| WACC | 7.47% |